logo
A beer pioneer, South Africa's first Black female brewery owner trains a new generation

A beer pioneer, South Africa's first Black female brewery owner trains a new generation

Yahoo2 days ago
JOHANNESBURG (AP) — After pouring brown, gritty liquid from a huge silver tank into a flute-like container known as a refractometer, South African beer brewing master Apiwe Nxusani-Mawela gives an expert nod of approval and passes it around to her students, who yell their observations with glee.
'When you are brewing you must constantly check your mixture,' Nxusani-Mawela instructs them. 'We are looking for a balance between the sugar and the grains.'
The 41-year-old Nxusani-Mawela is an international beer judge and taster, and is believed to be the first Black woman in South Africa to own a craft brewery, a breakthrough in a world largely dominated by men and big corporations. Her desire is to open South Africa's multibillion-dollar beer-brewing industry to more Black people and more women.
At her microbrewery in Johannesburg, she's teaching 13 young Black graduates — most of them women — the art of beer making.
The science behind brewing
The students at the Brewsters Academy have chemical engineering, biotechnology or analytical chemistry degrees and diplomas, but are eager to get themselves an extra qualification for a possible career in brewing.
Wearing hairnets and armed with barley grains and water, the scientists spend the next six hours on the day's lesson, learning how to malt, mill, mash, lauter, boil, ferment and filter to make the perfect pale ale.
'My favorite part is the mashing," said Lerato Banda, a 30-year-old chemical engineering student at the University of South Africa who has dreams of owning her own beer or beverage line. She's referring to the process of mixing crushed grains with hot water to release sugars, which will later ferment. "It's where the beer and everything starts.'
Nxusani-Mawela's classes began in early June. Students will spend six months exploring beer varieties, both international and African, before another six months on work placement.
Beer is for everyone
Nxusani-Mawela's Tolokazi brewery is in the Johannesburg suburb of Wynberg, wedged between the poor Black township of Alexandra on one side and the glitzy financial district of Sandton — known as Africa's richest square mile — on the other.
She hails from the rural town of Butterworth, some 1,000 kilometers (621 miles) away, and first came across the idea of a career in beer at a university open day in Johannesburg. She started brewing as an amateur in 2007. She has a microbiology degree and sees beer making as a good option for those with a science background.
'I sort of fell in love with the combination of the business side with the science, with the craftsmanship and the artistic element of brewing,' she said.
For the mother of two boys, beer brewing is also ripe for a shakeup.
'I wanted to make sure that being the first Black female to own a brewery in South Africa, that I'm not the first and the last,' she said. 'Brewsters Academy for me is about transforming the industry ... What I want to see is that in five, 10 years from now that it should be a norm to have Black people in the industry, it should be a norm to have females in the industry."
South Africa's beer industry supports more than 200,000 jobs and contributes $5.2 billion to South Africa's gross domestic product, according to the most current Oxford Economics research in 'Beer's Global Economic Footprint.' While South Africa's brewing sector remains male-dominated, like most places, efforts are underway to include more women.
One young woman at the classes, 24-year-old Lehlohonolo Makhethe, noted women were historically responsible for brewing beer in some African cultures, and she sees learning the skill as reclaiming a traditional role.
"How it got male dominated, I don't know,' Makhethe said. 'I'd rather say we are going back to our roots as women to doing what we started.'
With an African flavor
While Nxusani-Mawela teaches all kinds of styles, she also is on a mission to keep alive traditional African beer for the next generation. Her Wild African Soul beer, a collaboration with craft beer company Soul Barrel Brewing, was the 2025 African Beer Cup champion. It's a blend of African Umqombothi beer — a creamy brew incorporating maize and sorghum malt — with a fruity, fizzy Belgian Saison beer.
'Umqombothi is our African way, and everybody should know how to make it, but we don't,' she said. 'I believe that the beer styles that we make need to reflect having an element of our past being brought into the future.'
She's used all sorts of uniquely African flavors in her Tolokazi line, including the marula fruit and the rooibos bush that's native to South Africa and better-known for being used in a popular caffeine-free tea.
'Who could have thought of rooibos beer?' said Lethabo Seipei Kekae after trying the beer for the first time at a beer festival. 'It's so smooth. Even if you are not a beer drinker, you can drink it.'
___
AP Africa news: https://apnews.com/hub/africa
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025
Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

Yahoo

time11 hours ago

  • Yahoo

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

RAHWAY, N.J., July 08, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) taking place July 13-17, 2025, in Kigali, Rwanda. Merck will share new scientific findings from its HIV clinical development programs, including Phase 2 data on the safety and pharmacokinetics of MK-8527, an investigational, novel nucleoside reverse transcriptase translocation inhibitor (NRTTI), dosed orally once monthly, in development for the prevention of HIV as pre-exposure prophylaxis (PrEP). HIV clinical data presented at IAS 2025 from three Phase 3 trials (P051: NCT05631093; P052: NCT05630755; P054: NCT05766501) will examine the impact of preexisting resistance-associated mutations (RAMs) in proviral DNA on the virologic response to doravirine/islatravir (DOR/ISL), with a primary focus on M184I/V in proviral DNA. Data will also be presented on the clinical development program for a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for the treatment of adults with HIV-1 infection. Data from two Phase 1 trials evaluating the safety and tolerability of weekly ulonivirine and drug interactions between islatravir and ulonivirine dosed weekly in adults without HIV and a Phase 2b dose-ranging study utilizing a higher (20mg) dose of islatravir and 3 doses of ulonivirine in treatment naive adults living with HIV-1 will be presented. Based on results from these trials and pharmacokinetic modeling that will also be presented, a once-weekly oral combination of islatravir (2mg) and ulonivirine (200mg) (MK-8591B) is moving forward in clinical development. "As we continue to advance our HIV research, we are excited to present data from across our HIV pipeline at IAS 2025, including new data from our nucleoside reverse transcriptase translocation inhibitors development programs," said Dr. Elizabeth Rhee, vice president, global clinical development, Merck Research Laboratories. "With daily, weekly and monthly oral regimens in development, we aim to offer choices that can help address the evolving needs of individuals living with or impacted by HIV." Select abstracts in the IAS 2025 program include: Abstract Title and Author Date HIV PREVENTION Safety and Pharmacokinetics of Once-Monthly MK-8527: a Phase 2 Study in Adults at Low Risk of HIV-1 Exposure, Mayer, K, et al. Late-Breaker Oral Presentation Wednesday, July 16, 2025 (15:00 – 16:00 CAT) HIV TREATMENT Switching to Doravirine/Islatravir (100mg/0.25mg) Once Daily Maintained Viral Suppression in the Presence of Archived M184I/V Resistance-Associated Mutations in Proviral DNA, Diamond, T, et al. Poster Session Wednesday, July 16, 2025 (12:15 – 13:15 CAT) A Double-Blind, Active-Controlled, Phase 2b Study to Evaluate the Efficacy and Safety of Ulonivirine in Combination with Islatravir in Virologically Suppressed Adults Living With HIV-1, Molina, J.M., et al. (*) Oral Presentation ART Strategies Tuesday, July 15, 2025 (10:45 – 11:45 CAT) A Double-Blind Placebo-Controlled, Phase 1 Study to Evaluate Extended Multiple Dosing of Ulonivirine (MK-8507) in Adults Without HIV, Nussbaum, J, et al. Virtual Poster An Open-Label Phase 1 Study to Evaluate Drug Interactions Between Multiple Weekly Doses of Ulonivirine (MK-8507) and Single Doses of Islatravir in Adults Without HIV, Nussbaum, J, et al. Virtual Poster Phase 2 Once-Weekly Dose Optimization for Ulonivirine (MK-8507) in Combination with Islatravir (2mg), Pham, M, et al. Virtual Poster (*) Previous ulonivirine development program utilizing a higher (20mg) dose of islatravir. This year at IAS, Merck will host a policy symposium "Harnessing the Private Sector to Deliver HIV Prevention" on Tuesday, July 15, from 18:00 – 19:30 CAT. Merck will also host a medical symposium "Let's Talk About It – Practical Case Discussions" on Wednesday, July 16, from 12:15 – 13:15 CAT, which will cover critical considerations when treating HIV today, as well as a deep dive into the DOR/ISL resistance profile based on Phase 3 data. Both events will be open to all registered attendees, virtually and in-person. Separately, Merck will be hosting a virtual investor event where scientific and commercial leaders will give an overview of the company's advancing research pipeline in HIV treatment and prevention on Thursday, July 17, at 9:00AM ET. Investors, analysts, members of the media, and the general public are invited to listen to a webcast of the presentation at this weblink. For more details about Merck's clinical development program in HIV treatment and prevention, click here. Merck's Commitment to HIVFor more than 35 years, Merck has been committed to scientific research and discovery in HIV leading to scientific breakthroughs that have helped change HIV treatment. Our work has helped pioneer the development of new options across multiple drug classes to help those impacted by HIV. Today, we are developing a series of antiviral options designed to help people manage their HIV and to help prevent HIV, with the goal of reducing the growing burden of infection worldwide. We want to ensure people are not defined by HIV, and our work focuses on transformational innovations, collaborations with others in the global HIV community, and access initiatives aimed at helping to end the HIV epidemic for everyone. Indications and usage for PIFELTRO® (doravirine) and DELSTRIGO® (doravirine, lamivudine, and tenofovir disoproxil fumarate) in the is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adult patients with no prior ARV treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine. DELSTRIGO is indicated as a complete regimen for the treatment of HIV-1 infection in adult patients with no prior ARV treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO. Selected Safety Information Warning: Posttreatment Acute Exacerbation of Hepatitis B Virus (HBV) for DELSTRIGOAll patients with HIV-1 should be tested for the presence of HBV before initiating ARV therapy. Severe acute exacerbations of HBV have been reported in people with concomitant HIV-1 and HBV who have discontinued products containing lamivudine or tenofovir disoproxil fumarate (TDF), which are components of DELSTRIGO. Patients coinfected with HIV-1 and HBV who discontinue DELSTRIGO should be monitored with both clinical and laboratory follow-up for at least several months after stopping DELSTRIGO. If appropriate, initiation of anti-HBV therapy may be warranted. ContraindicationsPIFELTRO and DELSTRIGO are contraindicated when coadministered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers (including the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and phenytoin; the androgen receptor inhibitor enzalutamide; the antimycobacterials rifampin and rifapentine; the cytotoxic agent mitotane; and the herbal product St. John's wort (Hypericum perforatum)), as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of DELSTRIGO and PIFELTRO. DELSTRIGO is contraindicated in patients with a previous hypersensitivity reaction to lamivudine. Warnings and PrecautionsSevere Skin ReactionsSevere skin reactions, including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), have been reported during the postmarketing experience with doravirine-containing regimens. Discontinue PIFELTRO or DELSTRIGO, and other medications known to be associated with severe skin reactions, immediately if a painful rash with mucosal involvement or a progressive severe rash develops. Clinical status should be closely monitored, and appropriate therapy should be initiated. New or Worsening Renal ImpairmentRenal impairment, including cases of acute renal failure and Fanconi syndrome, have been reported with the use of TDF. DELSTRIGO should be avoided with concurrent or recent use of a nephrotoxic agent (eg, high-dose or multiple NSAIDs). Cases of acute renal failure after initiation of high-dose or multiple NSAIDs have been reported in people living with HIV with risk factors for renal dysfunction who appeared stable on TDF. Prior to or when initiating DELSTRIGO, and during treatment, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. Discontinue DELSTRIGO in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. Discontinue DELSTRIGO if estimated creatinine clearance declines below 50 mL/min. Bone Loss and Mineralization DefectsIn clinical trials in adults living with HIV, TDF was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism. Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher. Cases of osteomalacia associated with proximal renal tubulopathy have been reported with the use of TDF. The effects of TDF-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk in adults are unknown. Immune Reconstitution SyndromeImmune reconstitution syndrome can occur, including the occurrence of autoimmune disorders with variable time to onset, which may necessitate further evaluation and treatment. Drug InteractionsBecause DELSTRIGO is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. Coadministration of PIFELTRO with efavirenz, etravirine, or nevirapine is not recommended. If DELSTRIGO is coadministered with rifabutin, take one tablet of DELSTRIGO once daily, followed by one tablet of doravirine (PIFELTRO) approximately 12 hours after the dose of DELSTRIGO. If PIFELTRO is coadministered with rifabutin, increase PIFELTRO dosage to one tablet twice daily (approximately 12 hours apart). Consult the full Prescribing Information prior to and during treatment for more information on potential drug-drug interactions. Dosage and Administration/Specific PopulationsRenal ImpairmentBecause DELSTRIGO is a fixed-dose combination tablet and the dosage of lamivudine and TDF cannot be adjusted, DELSTRIGO is not recommended in patients with estimated creatinine clearance less than 50 mL/min. Adverse ReactionsThe most common adverse reactions with DELSTRIGO (incidence ≥5%, all intensities) were dizziness (7%), nausea (5%), and abnormal dreams (5%). The most common adverse reactions with PIFELTRO (incidence ≥5%, all intensities) were nausea (7%), dizziness (7%), headache (6%), fatigue (6%), diarrhea (6%), abdominal pain (5%), and abnormal dreams (5%). By week 96 in DRIVE-FORWARD, 2% of adult participants in the PIFELTRO group and 3% in the darunavir+ritonavir (DRV+r) group had adverse events leading to discontinuation of study medication. By week 96 in DRIVE-AHEAD, 3% of adult participants in the DELSTRIGO group and 7% in the efavirenz (EFV)/emtricitabine (FTC)/TDF group had adverse events leading to discontinuation of study medication. In DRIVE-FORWARD, mean changes from baseline at week 48 in LDL-cholesterol (LDL-C) and non-HDL-cholesterol (non-HDL-C) were pre-specified. LDL-C: -4.6 mg/dL in the PIFELTRO group vs 9.5 mg/dL in the DRV+r group. Non-HDL-C: -5.4 mg/dL in the PIFELTRO group vs 13.7 mg/dL in the DRV+r group. The clinical benefits of these findings have not been demonstrated. In DRIVE-AHEAD, mean changes from baseline at week 48 in LDL-C and non-HDL-C were pre-specified. LDL-C: -2.1 mg/dL in the DELSTRIGO group vs 8.3 mg/dL in the EFV/FTC/TDF group. Non-HDL-C: -4.1 mg/dL in the DELSTRIGO group vs 12.7 mg/dL in the EFV/FTC/TDF group. The clinical benefits of these findings have not been demonstrated. In DRIVE-SHIFT, mean changes from baseline at week 24 in LDL-C and non-HDL-C were pre-specified. LDL-C: -16.3 mg/dL in the DELSTRIGO group vs -2.6 mg/dL in the PI + ritonavir group. Non-HDL-C: -24.8 mg/dL in the DELSTRIGO group vs -2.1 mg/dL in the PI + ritonavir group. The clinical benefits of these findings have not been demonstrated. In DRIVE-AHEAD, neuropsychiatric adverse events were reported in the three pre-specified categories of sleep disorders and disturbances, dizziness, and altered sensorium. Twelve percent of adult participants in the DELSTRIGO group and 26% in the EFV/FTC/TDF group reported neuropsychiatric adverse events of sleep disorders and disturbances; 9% in the DELSTRIGO group and 37% in the EFV/FTC/TDF group reported dizziness; and 4% in the DELSTRIGO group and 8% in the EFV/FTC/TDF group reported altered sensorium. The safety of DELSTRIGO in virologically-suppressed adults was based on week 48 data from participants in the DRIVE-SHIFT trial. Overall, the safety profile in virologically-suppressed adult participants was similar to that in participants with no ARV treatment history. Serum ALT and AST Elevations: In the DRIVE-SHIFT trial, 22% and 16% of participants in the immediate switch group experienced ALT and AST elevations greater than 1.25 X ULN, respectively, through 48 weeks on DELSTRIGO. For these ALT and AST elevations, no apparent patterns with regard to time to onset relative to switch were observed. One percent of participants had ALT or AST elevations greater than 5 X ULN through 48 weeks on DELSTRIGO. The ALT and AST elevations were generally asymptomatic, and not associated with bilirubin elevations. In comparison, 4% and 4% of participants in the delayed switch group experienced ALT and AST elevations of greater than 1.25 X ULN through 24 weeks on their baseline regimen. Pregnancy/BreastfeedingThere is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to PIFELTRO or DELSTRIGO during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263. Inform individuals with HIV-1 infection of the potential risks of breastfeeding, including: (1) HIV-1 transmission (in HIV-1–negative infants), (2) developing viral resistance (in HIV-1–positive infants), and (3) serious adverse reactions in a breastfed infant similar to those seen in adults. About MerckAt Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USAThis news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( Please see Prescribing Information for PIFELTRO (doravirine) at: and Patient Information for PIFELTRO at: Please see Prescribing Information for DELSTRIGO (doravirine, lamivudine, and tenofovir disoproxil fumarate) at: and Patient Information for DELSTRIGO at: View source version on Contacts Media Contacts:Julie Cunningham, (617) 519-6264Deb Wambold, (215) 779-2234Investor Contacts:Peter Dannenbaum, (732) 594-1579Steven Graziano, (732) 594-1583 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

First malaria treatment for babies and infants approved for use
First malaria treatment for babies and infants approved for use

Yahoo

time12 hours ago

  • Yahoo

First malaria treatment for babies and infants approved for use

The first malaria treatment for babies and young children has been approved for use. The treatment is dissolvable, including in breast milk, and has a sweet cherry flavour to make it easier to administer. Eight countries took part in a trial for the new treatment - Burkina Faso, Cote d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania and Uganda - and it is expected to be rolled out across Africa in a matter of weeks. Until now, there has been no approved malaria treatment for infants weighing less than 4.5kg (around 10lb). Instead, young infants have been treated with versions made for older children. This brought with it a risk of overdose, because infant livers are not fully developed. "The available malaria treatments have only been properly tested in children aged at least six months because smaller infants are usually excluded from treatment trials," said Professor Umberto D'Alessandro, from the London School of Hygiene and Tropical Medicine. Around 30 million babies are born in areas of malaria risk every year, with one survey reporting infections ranging between 3.4% and 18.4% in infants less than six months old. The drug, known as Coartem Baby or Riamet Baby, will be available on a largely not-for-profit basis, the company behind it, Novartis, has said. In March, scientists said they were genetically modifying mosquitoes in a bid to stop the spread of the disease. It would mean a mosquito bite in regions of the world where the disease is endemic no longer carries a potential death sentence. It comes as scientists warned more than half of the world's population could be at risk of catching diseases transmitted by mosquitoes such as malaria and dengue by the end of the century

Meet the woman breaking barriers in South Africa's $5 billion beer industry
Meet the woman breaking barriers in South Africa's $5 billion beer industry

Fast Company

timea day ago

  • Fast Company

Meet the woman breaking barriers in South Africa's $5 billion beer industry

After pouring brown, gritty liquid from a huge silver tank into a flute-like container known as a refractometer, South African beer brewing master Apiwe Nxusani-Mawela gives an expert nod of approval and passes it around to her students, who yell their observations with glee. 'When you are brewing you must constantly check your mixture,' Nxusani-Mawela instructs them. 'We are looking for a balance between the sugar and the grains.' The 41-year-old Nxusani-Mawela is an international beer judge and taster, and is believed to be the first Black woman in South Africa to own a craft brewery, a breakthrough in a world largely dominated by men and big corporations. Her desire is to open South Africa's multibillion-dollar beer-brewing industry to more Black people and more women. At her microbrewery in Johannesburg, she's teaching 13 young Black graduates—most of them women—the art of beer making. The science behind brewing The students at the Brewsters Academy have chemical engineering, biotechnology or analytical chemistry degrees and diplomas, but are eager to get themselves an extra qualification for a possible career in brewing. Wearing hairnets and armed with barley grains and water, the scientists spend the next six hours on the day's lesson, learning how to malt, mill, mash, lauter, boil, ferment and filter to make the perfect pale ale. 'My favorite part is the mashing,' said Lerato Banda, a 30-year-old chemical engineering student at the University of South Africa who has dreams of owning her own beer or beverage line. She's referring to the process of mixing crushed grains with hot water to release sugars, which will later ferment. 'It's where the beer and everything starts.' Nxusani-Mawela's classes began in early June. Students will spend six months exploring beer varieties, both international and African, before another six months on work placement. Beer is for everyone Nxusani-Mawela's Tolokazi brewery is in the Johannesburg suburb of Wynberg, wedged between the poor Black township of Alexandra on one side and the glitzy financial district of Sandton—known as Africa's richest square mile—on the other. She hails from the rural town of Butterworth, some 1,000 kilometers (621 miles) away, and first came across the idea of a career in beer at a university open day in Johannesburg. She started brewing as an amateur in 2007. She has a microbiology degree and sees beer making as a good option for those with a science background. 'I sort of fell in love with the combination of the business side with the science, with the craftsmanship and the artistic element of brewing,' she said. For the mother of two boys, beer brewing is also ripe for a shakeup. 'I wanted to make sure that being the first Black female to own a brewery in South Africa, that I'm not the first and the last,' she said. 'Brewsters Academy for me is about transforming the industry . . . What I want to see is that in five, 10 years from now that it should be a norm to have Black people in the industry, it should be a norm to have females in the industry.' South Africa's beer industry supports more than 200,000 jobs and contributes $5.2 billion to South Africa's gross domestic product, according to the most current Oxford Economics research in 'Beer's Global Economic Footprint.' While South Africa's brewing sector remains male-dominated, like most places, efforts are underway to include more women. One young woman at the classes, 24-year-old Lehlohonolo Makhethe, noted women were historically responsible for brewing beer in some African cultures, and she sees learning the skill as reclaiming a traditional role. 'How it got male dominated, I don't know,' Makhethe said. 'I'd rather say we are going back to our roots as women to doing what we started.' With an African flavor While Nxusani-Mawela teaches all kinds of styles, she also is on a mission to keep alive traditional African beer for the next generation. Her Wild African Soul beer, a collaboration with craft beer company Soul Barrel Brewing, was the 2025 African Beer Cup champion. It's a blend of African Umqombothi beer—a creamy brew incorporating maize and sorghum malt—with a fruity, fizzy Belgian Saison beer. 'Umqombothi is our African way, and everybody should know how to make it, but we don't,' she said. 'I believe that the beer styles that we make need to reflect having an element of our past being brought into the future.' She's used all sorts of uniquely African flavors in her Tolokazi line, including the marula fruit and the rooibos bush that's native to South Africa and better-known for being used in a popular caffeine-free tea.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store